Effective treatment strategies for paediatric community-acquired pneumonia

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 8, 2007, Pages 1091-1101

  Atkinson, Maria ^a   Yanney, Michael ^a   Stephenson, Terence ^b   Smyth, Alan ^c  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Community acquired pneumonia; Paediatric

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; MACROLIDE; METHYLPREDNISOLONE; OSELTAMIVIR; OXYGEN; PALIVIZUMAB; PENICILLIN DERIVATIVE; PENICILLIN G; PNEUMOCOCCUS VACCINE; PREDNISOLONE; PROCAINE PENICILLIN; PROCALCITONIN; RETINOL; RIBAVIRIN; VITAMIN D;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIAL VIRULENCE; BACTERIUM CULTURE; CAUSE OF DEATH; CHILD; CHILD CARE; CHILDHOOD MORTALITY; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DISEASE ASSOCIATION; DRUG ADMINISTRATION ROUTE; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; EMPYEMA; ESCHERICHIA COLI; GRAM POSITIVE BACTERIUM; HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE TEST; INDIVIDUALIZATION; INFECTION CONTROL; INFLUENZA; INFLUENZA VIRUS; INTERNET; LEUKOCYTE COUNT; LUNG ABSCESS; LUNG ASPIRATION; MALNUTRITION; MEASLES; MEASLES VIRUS; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METAPNEUMOVIRUS; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MORBIDITY; MYCOPLASMA PNEUMONIAE; PATHOGENESIS; PATIENT CARE; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; REVIEW; RICKETS; RISK FACTOR; SARS CORONAVIRUS; SENSITIVITY AND SPECIFICITY; SEROLOGY; SEVERE ACUTE RESPIRATORY SYNDROME; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; SUN EXPOSURE; TACHYPNEA; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT FAILURE; VIRUS CULTURE; VIRUS PNEUMONIA; VITAMIN SUPPLEMENTATION;

ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; INCIDENCE; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE;

EID: 34250628847     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.8.1091     Document Type: Review

References (63)

1. BRYCE J, BOSCHI-PINTO C, SHIBUYA K, BLACK RE: VVHO Child Health Epidemiology Reference Group. WHO estimates of the causes of death in children. Lancet (2005) 365:1147-1152.
2. RUUSKANEN O, MERTSOLA J: Childhood community-acquired pneumonia. Semin. Respir. Infect. (1999) 14:163-172.
3. MACINTYRE C, MACINTYRE P, CAGNEY M: Community-based estimates of incidence and risk factors for childhood pneumonia in Western Sydney. Epidemiol. Infect. (2003) 131:1091-1096.
4. JOKINEN C, HEISKANEN L, JUVONEN H et al.: Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am. J. Epidemiol. (1993) 137:977-988.
5. MCINTOSH E, BOOY R: Invasive pneumococcal disease in England and Wales: what is the true burden and what is the potential for prevention using 7 valent pneumococcal conjugate vaccine? Arch. Dis. Child. (2002) 86:403-406.
6. Technical bases for the WHO recommendations on the management of pneumonia in children at first-level health facilities. World Health Organisation, Geneva (1991).
7. The management of acute respiratory infections in children. Practical guidelines for out-patient care. World Health Organisation, Geneva (1995)
8. SMYTH A, CARTY H, HART CA: Clinical predictors of hypoxaemia in children with pneumonia. Ann. Trop. Paediatr. (1998) 18(1):31-40.
9. SMYTH A, RIDWAN R, CAIRNS J: Impact of a case management protocol for childhood pneumonia in a rural Zambian hospital. Ann. Trop. Paediatr. (1998) 18(2):155-160.
10. KIEKARA O, KORPPI M, TANSKA S, SOIMAKALLIO S: Radiological diagnosis of pneumonia in children. Ann. Med. (1996) 28:69-72.
11. CHERIAN T, MULHOLLAND E, CARLIN J et al.: Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull. World Health Organ. (2005) 83:353-359.
12. DAVIES H, WANG E, MANSON D, BABYN P, SHUCKETT B: Reliability of the chest radiograph in the diagnosis of lower respiratory infections in young children. Pediatr. Infect. Dis. J. (1996) 17(7):600-604.
13. SWISCHUK L, HAYDEN C: Viral versus bacterial pulmonary infections in children (is roentgenographic differentiation possible?). Pediatr. Radiol. (1986) 16:278-284.
14. BETTENAY F, DE CAMPO J, MCCROSSIN D: Differentiating bacterial from viral pneumonias in children. Pediatr. Radiol. (1988) 18:453-454.
15. VIRKKI R, JUVEN T, RIKALAINEN H et al.: Differentiation of bacterial and viral pneumonia in children. Thorax (2002) 57:438-441.
16. SWINGLER GH, ZWARENSTEIN M: Chest radiograph in acute respiratory infections in children. Cochrane Database Syst. Rev. (2005) (3): CDO01268, PMID:10796627.
17. CLEMENTS H, STEPHENSON T, GABRIEL V et al.: Rationalised prescribing for community acquired pneumonia; a closed loop audit. Arch. Dis. Child. (2000) 83:320-324.
18. DRUMMOND P, CLARK J, WHEELER J et al.: Community Acquired Pneumonia - a propsective UK study. Arch. Dis. Child. (2000) 83:408-412.
19. EPOSITO S, BLASI F, BELLINI E ALLEGRA L, PRINCIPI N: Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with pneumonia. Eur. Respir. J. (2001) 17:241-254.
20. KORPPI M: Aetiology of community-acquired pneumonia in children treated in hospital. Eur. J. Pediatr. (1993) 152:24-30.
21. MOULIN F, RAYMOND J, LORROT M et al.: Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch. Dis. Child. (2001) 84(4):332-336.
22. TOIKKA P, IRJALA K, JUVEN T et al.: Serum procalcitonin, C-reactive protein and IL-6 for distinguishing bacterial and viral pneumonia in children. Pediatr. Infect. Dis. J. (2000) 19(7):598-602.
23. NOHYNEK H, ESKOLA J, LAINE E et al.: The causes of hospital-treated acute lower respiratory tract infection in children. Am. J. Dis. Child. (1991) 145:618-622.
24. CLAESSON B, TROLLFORS B, BROLIN I, GRANSTROM M, HENRICHSEN J: Etiology of community-acquired pneumonia in children based on antibiody responses to bacterial and viral antigens. Pediatr. Infect. Dis. J. (1989) 8:856-862.
25. WUBBEL L, MUNIZ L, AHMED A: Etiology and treatment of community acquired pneumonia in ambulatory children. Pediatr Infect. Dis. J. (1999) 18:98-104.
26. JUVEN T, MERTSOLA J, WARIS M: Etiology of community acquired pneumonia in 254 hospitalized children. Pediatr. Infect. Dis. J. (2000) 19:293-298.
27. TOIKKA P, JUVEN T, VIRKKI R, LEINONEN M, MERTSOLA J, RUUSKANEN 0: Streptococcus pneumoniae and Mycoplasma pneumoniae coinfection in community acquired pneumonia. Arch. Dis. Child. (2000) 83:413-414.
28. WILLIAMS JV, HARRIS PA, TOLLEFSON SJ et al.: Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N. Engl. J. Med. (2004) 350(5):443-450.
29. CLARK JE, HAMPTON F: The burden of pneumonia in the UK. Arch. Dis. Child. (2003) 88(Suppl. 1):A43.
30. BLOCK S, HEDRICK J, HAMMERSCHLAG MR, CASSELL G, CRAFT J: Mycoplasma pneumoniae and Chlamydia pneumonia in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin versus eryhtromycin ethylsuccinate. Pediatr. Infect. Dis. J. (1995) 14:471-477.
31. MICHELOW I, OLSEN K, LOZANO J et al.: Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics (2004) 113(4):701-707.
32. FOY HM: Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin. Infect. Dis. (1993) 17(Suppl. 1):S37-S46.
33. GENDREL D, RAYMOND J, MOULIN F et al.: Etiology and response to antibiotic therapy of community acquired pneumonia in French children. Eur. J. Clin. Microbiol. Infect. Dis. (1997) 16:388-391.
34. MUHE L, LULSEGED S, MASON KE, SIMOES EAF: Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children. Lancet (1997) 349(9068):1801-1804.
35. CHINTU C, LUO C, BHAT G et al.: Impact of the human immunodeficiency virus type-1 on common pediatric illnesses in Zambia. J. Trop. Pediatr. (1995) 41(6):348-353.
36. SMYTH A, TONG CYW, CARTY H, HART CA: Impact of HIV on mortality from acute lower respiratory tract infection in rural Zambia. Arch. Dis. Child. (1997) 77(3):227-230.
37. KABRA SK, LODHA R, PANDEY RM: Antibiotics for community acquired pneumonia in children. Cochrane Database Syst. Rev. (2006) (3):CD004874; PMID:14651858.
38. GAVRANICH JB, CHANG AB: Antibiotics for community acquired lower respiratory tract infections (LRTI) secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst. Rev. (2005) (3):CD004875; PMID:14651858.
39. HON KLE, LEUNG CW, CHENG WT et al.: Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet (2003) 361(9370):1701-1703.
40. PICKLES H: Using lessons from the past to plan for pandemic flu. Br. Med. J. (2006) 332(7544):783-786.
41. FRY J: Influenza, 1959: The story of an epidemic. Br. Med. J. (1959) 5144:135-138.
42. SHANN F, D'SOUZA RM, D'SOUZA R: Antibiotics for preventing pneumonia in children with measles. Cochrane Database Syst. Rev. (2000) (3):CD001477; PMID: 10796647.
43. GARLY M-L, BALE C, MARTINS CL et al.: Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau. Br. Med. J. (2006) 333:1245-1247.
44. HUIMING Y, CHAOMIN W, MENG M: Vitamin A for treating measles in children. Cochrane Database Syst. Rev. (2005) (4):CD001479; PMID: 11869601.
45. FELMINGHAM D, FARRELL D, REINHART R, MORRISSEY I: Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999 - 2000). J. Infect. (2004) 48:39-55.
46. WHITNEY CG, FARLEY MM, HADLER J et al.: Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the US. N. Engl. J. Med. (2000) 343(26):1917-1924.
47. ADDO-YOBO E, CHISAKA N, HASSAN M et al.: Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 - 59 months: a randomised multicentre equivalency study. Lancet (2004) 364:1141-1148.
48. CAMPBELL M, BYASS P, FORGIE I et al.: Trial of co-trimoxazole versus procaine penicillin with ampcillin in treatment of community acquired pneumonia in young Gambian children. Lancet (1988) 19:1182-1184.
49. KEELEY D, NKRUMAH F, KAPUYANYIKA C: Randomised trial of sulfamethoxazole and trimethoprim versus procine penicillin for the out-patient treatment of childhood pneumonia in Zimbabwe. Bull. World Health Organ. (1990) 68:185-192.
50. SIDAL M, OGUZ F, UNAVAR A: Trial of co-trimoxazole versus procaine penicillin G, and benzathin penicillin and procaine penicillin G in the treatment of childhood pneumonia. J. Trop. Pediatr. (1994) 40:301-304.
51. TSAROUHAS N, SHAW K, HODINKA R, BELL L: Effectiveness of intramuscular penicillin versus oral amoxicillin in the early treatment of outpatient pediatric pneumonia. Pediatr. Emerg. Care (1998) 14(5):338-341.
52. ATKINSON M, LAKHANPAUL M, SMYTH A et al.: A randomised controlled equivalence trial comparing oral amoxicillin and IV benzyl penicillin for community acquired pneumonia in children PIVOT Trial. Accepted for publication by the British Medical Journal (2006)
53. AL-EIDAN FA, MCELNAY JC, SCOTT MG et al.: Sequential antimicrobial therapy: treatment of severe lower respiratory tract infections in children. J. Antimicrob. Chemother. (1999) 44(5):709-715.
54. DI CIOMMO V, RUSSO P, ATTANASIO E et al.: Clinical and economic outcomes of pneumonia in children: a longitudinal observational study in an Italian paediatric hospital. J. Eval. Clin. Pract. (2002) 8(3):341-348.
55. ISCAP STUDY GROUP: 3 day versus 5 day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controllled trial. Br. Med. J. (2004) 328:791-794.
56. MASCOT STUDY GROUP: Clinical efficacy of 3 day versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double blind trial. Lancet (2002) 360:835-841.
57. SPENCER DA, IQBAL SM, HASAN A, HAMILTON L: Empyema thoracis is still increasing in UK children. Br. Med. J. (2006) 332(7553):1333.
58. TAN T, MASON E: Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics (2002) 110:1-6.
59. EASTHAM K, FREEMAN R, KEARNS A et al.: Clinical features, aetiology and outcome of empyema in children in the north east of England. Thorax (2004) 59:522-525.
60. British National Formulary for Children. Mehra D (Ed.). BMJ Publishing Group Ltd, RPS Publishing, RCPCH Publications Ltd. (2006).
61. BLACK S, SHIENFIELD H, FIREMEN B: Efficacy; safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. (2000) 19(187-195)
62. BRITISH THORACIC SOCIETY OF STANDARDS OF CARE COMMITTEE: BTS guidelines for the management of community acquired pneumonia in childhood. Thorax (2002) 57(Suppl. 1):i1-i24.
63. DELLIT TH, OWENS RC, MCGOWAN JE et al.: Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. (2007) 44:159-177.